ADC Therapeutics (ADCT) Operating Income (2019 - 2023)
Historic Operating Income for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$36.1 million.
- ADC Therapeutics' Operating Income fell 106085.42% to -$36.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$10.8 billion, marking a year-over-year increase of 8278.24%. This contributed to the annual value of $4950.0 for FY2022, which is 10189.13% up from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Operating Income is -$36.1 million, which was down 106085.42% from $3.0 billion recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Operating Income registered a high of $3.0 billion during Q2 2023, and its lowest value of -$62.8 billion during Q4 2021.
- Its 5-year average for Operating Income is -$4.2 billion, with a median of -$36.1 million in 2023.
- Per our database at Business Quant, ADC Therapeutics' Operating Income plummeted by 16102302863.17% in 2021 and then skyrocketed by 445233.61% in 2023.
- Over the past 5 years, ADC Therapeutics' Operating Income (Quarter) stood at -$35732.0 in 2019, then soared by 99.85% to -$52.43 in 2020, then plummeted by 119747081612.06% to -$62.8 billion in 2021, then skyrocketed by 82.9% to -$10.7 billion in 2022, then skyrocketed by 99.66% to -$36.1 million in 2023.
- Its Operating Income was -$36.1 million in Q3 2023, compared to $3.0 billion in Q2 2023 and -$51.6 million in Q1 2023.